title: Lack of induction of autoantibody responses following immunization with cytomegalovirus (CMV) glycoprotein B (gB) in healthy CMV-seronegative subjects.
abstract: Possible correlations have been proposed between autoimmune diseases, such as systemic lupus erythematosus (SLE), and infection with human cytomegalovirus (CMV). The recent observation that an adenovirus expressing the immunodominant envelope glycoprotein of CMV, glycoprotein B (gB), may be capable of inducing autoantibodies in certain mouse strains has prompted interest in exploring potential relationships between gB immunization and autoimmune disease. We examined whether a recombinant CMV gB vaccine, or a gB canarypox vectored vaccine (ALVAC-CMVgB), administered to a total of 76 CMV-seronegative subjects, was capable of inducing cross-reactive antibodies to Smith antigen (Sm), ribonucleoprotein complex (RNP), and the U1-70 kDa component of the RNP complex. Using immunofluorescence, EIA and immunoblot analyses, we failed to identify induction of autoantibodies following vaccination with gB, whether administered alone as a purified protein subunit with adjuvant, or in combination with expression in a vectored approach using a recombinant canarypox. These data reinforce the favorable safety profile of CMV gB vaccines.
authors.affiliation: Division of Infectious Diseases, 3333 Burnet Avenue, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. schlm0@cchmc.org
authors.forename: Mark R
authors.initials: MR
authors.lastname: Schleiss
authors.forename: David I
authors.initials: DI
authors.lastname: Bernstein
authors.forename: Murray
authors.initials: M
authors.lastname: Passo
authors.forename: Susan
authors.initials: S
authors.lastname: Parker
authors.forename: Claude
authors.initials: C
authors.lastname: Meric
authors.forename: François
authors.initials: F
authors.lastname: Verdier
authors.forename: Marianna M
authors.initials: MM
authors.lastname: Newkirk
mesh_terms: D000293:Adolescent; D000328:Adult; D001323:Autoantibodies / Q000097:blood* / Q000276:immunology; D001324:Autoantigens / Q000276:immunology; D001327:Autoimmune Diseases / Q000276:immunology / Q000821:virology; D003587:Cytomegalovirus / Q000235:genetics / Q000276:immunology*; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D015151:Immunoblotting; D007124:Immunoenzyme Techniques; D008297:Male; D008875:Middle Aged; D017412:Ribonucleoprotein, U1 Small Nuclear / Q000276:immunology; D017411:Ribonucleoproteins, Small Nuclear / Q000276:immunology; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D014759:Viral Envelope Proteins / Q000008:administration & dosage / Q000276:immunology*; D055517:snRNP Core Proteins
chemical_list: D001323:Autoantibodies; D001324:Autoantigens; D017412:Ribonucleoprotein, U1 Small Nuclear; D017411:Ribonucleoproteins, Small Nuclear; C490688:SNRNP70 protein, human; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; C040495:glycoprotein B, Simplexvirus; D055517:snRNP Core Proteins